Old Web
English
Sign In
Acemap
>
authorDetail
>
Suchitrita Rathmann
Suchitrita Rathmann
Eli Lilly and Company
Psoriatic arthritis
Ixekizumab
Medicine
Internal medicine
Placebo
5
Papers
63
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Ixekizumab and complete resolution of enthesitis and dactylitis: Integrated analysis of two phase 3 randomized trials in psoriatic arthritis
2019
Arthritis Research & Therapy
Dafna D. Gladman
Ana-Maria Orbai
Uta Klitz
James Cheng-Chung Wei
Gaia Gallo
Julie Birt
Suchitrita Rathmann
David Shrom
Helena Marzo-Ortega
Show All
Source
Cite
Save
Citations (20)
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
2018
RMD Open
Peter Nash
Frank Behrens
Ana Maria Orbai
Suchitrita Rathmann
David H. Adams
O. Benichou
Atulya (Atul) Deodhar
Show All
Source
Cite
Save
Citations (9)
AB0944 Efficacy and safety of ixekizumab when used alone or in combination with conventional disease-modifying antirheumatic drugs (CDMARDS) in tnf-experienced patients with psoriatic arthritis
2018
Annals of the Rheumatic Diseases
Peter Nash
Frank Behrens
Ana-Maria Orbai
Suchitrita Rathmann
David H. Adams
O. Benichou
Atul Deodhar
Show All
Source
Cite
Save
Citations (1)
SAT0321 Ixekizumab treatment significantly improves enthesitis and dactylitis in patients with active psoriatic arthritis: results from the spirit trials
2018
Annals of the Rheumatic Diseases
Dafna D. Gladman
Ana-Maria Orbai
G. Gallo
Julie Birt
Suchitrita Rathmann
Helena Marzo-Ortega
Show All
Source
Cite
Save
Citations (0)
Choosing estimands in clinical trials with missing data
2017
Pharmaceutical Statistics
Craig H. Mallinckrodt
Geert Molenberghs
Suchitrita Rathmann
Show All
Source
Cite
Save
Citations (33)
1